| OCUGEN INC. DL-,001 |
| USA |
| Gesundheit |
| US67577C1053 / A2PSZH |
| 2H51 (Frankfurt) / OCGN (NASDAQ) |
| FRA:2H51, ETR:2H51, 2H51:GR, NASDAQ:OCGN |
| - |
| https://ocugen.com/ |
|
Ocugen Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and creating vaccines to combat infectious diseases. Primarily centered on advancing innovati..
>Volltext.. |
| 380.26 Mio. EUR |
| 380.6 Mio. EUR |
| 4.51 Mio. EUR |
| -47.38 Mio. EUR |
| -53.8 Mio. EUR |
| -0.18 EUR |
| 27.7 Mio. EUR |
| 27.37 Mio. EUR |
| -44.85 Mio. EUR |
| 1.6 |
| 8.41% |
| -18.77% |
| - |
| - |
| - |
| - |
| OCUGEN |
| 13.02.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|